Press Releases

2016
Pulmagen Therapeutics announces positive data for ADC3680, a once daily, orally administered CRTh2 antagonist in eosinophilic asthma patients in a 16-week Phase II study conducted in Japan by partner Teijin Pharma Limited

Slough, U.K., December 14th, 2016 --- Pulmagen Therapeutics (Asthma) Ltd announces positive data for PTR-36 (ADC3680), a once daily, orally administered CRTh2 antagonist in eosinophilic asthma patients in a 16-week Phase II double blind, placebo controlled study, that was conducted in Japan by Tokyo-based Teijin Pharma Limited, the core company of the Teijin Group’s healthcare business. Pulmagen licensed its CRTh2 programme including PTR-36 for Japan to Teijin Pharma in 2012.

Pulmagen is to seek a global partner for late stage clinical development. Read more>>>
2014
Skyepharma acquires a novel inhaled therapy platform SKP-2075, from Pulmagen Therapeutics to be developed as an anti-inflammatory treatment for COPD

New product opportunity - SKP-2075 - to be developed as an anti-inflammatory treatment for COPD
London, U.K / Slough, U.K., August 13th, 2014 --- Skyepharma PLC (LSE SKP), the expert oral and inhalation drug delivery company, today announces that it has acquired the global rights and related intellectual property (including granted patents and patent applications) to a novel inhaled therapy platform from Pulmagen Therapeutics (Synergy) Limited ("Pulmagen"). Skyepharma will apply its proven expertise in inhaled drug development to develop a first product (SKP-2075) for chronic obstructive pulmonary disease (COPD) through to the completion of a phase II efficacy and safety trial sized to produce clinically significant data. It will then seek to out-licence SKP-2075 to a pharmaceutical partner for late-stage development and commercialisation. Read more>>>
2012
Teijin Pharma and Pulmagen Therapeutics Sign Exclusive Agreement

Teijin to develop, manufacture and market Pulmagen-developed novel drug for bronchial asthma in Japan
Tokyo, Japan / Slough, U.K., September 26th, 2012 --- Tokyo-based Teijin Pharma Limited, the core company of the Teijin Group’s healthcare business, and Pulmagen Therapeutics (Asthma) Limited, a UK-based drug development company, announce today an exclusive licensing agreement granting Teijin Pharma the rights to develop, manufacture and market ADC3680, a bronchial asthma therapeutic discovered by Pulmagen Therapeutics, in Japan. Read more>>>
2011
Argenta Signs Integrated Services Agreement with Pulmagen Therapeutics

The deal with Argenta is part of a discovery and development collaboration that Pulmagen has established with Chiesi Farmaceutici S.p.A.
Mechelen, Belgium / Slough, U.K., 28th June 2011 --- Galapagos NV (Euronext: GLPG) announced today that service division Argenta has signed a subcontracting agreement with Pulmagen Therapeutics Limited to perform integrated services on two respiratory projects. Read more>>>
2010
Galapagos acquires Argenta Discovery’s service operations

Galapagos has paid €16.5 million cash for Argenta Discovery 2009 Ltd. Argenta’s respiratory development programs will continue as a new privately held company, Pulmagen Therapeutics
Mechelen, Belgium / Slough, U.K., 2nd February 2010 --- Galapagos NV (Euronext: GLPG) announces the acquisition of Argenta Discovery 2009 Ltd., a privately held contract research drug discovery company with 140 employees. The combination with Galapagos’ service division BioFocus creates one of the world’s largest drug discovery service organizations, with 390 employees, an estimated €70 million in annual turnover and significant profitability. The acquisition also brings additional capacity and drug discovery capabilities to the Galapagos Group. Read more>>>
2007
Pulmagen [known at the time as Argenta Discovery] and AstraZeneca sign a Research Collaboration and Licensing Agreement to Discover Improved Bronchodilators for COPD

Deal Provides Argenta With $21 Million Upfront plus Research Funding; Additional Milestone And Royalty Payments
Harlow, UK and London, UK – 31st January 2007 --- Argenta Discovery Limited, the respiratory drug discovery and development company, and AstraZeneca (AZ), today announce a major discovery alliance to identify improved bronchodilators to treat chronic obstructive pulmonary disease (COPD). Under the terms of the agreement, Argenta receives $21 million upfront plus further committed research funding and pre-clinical milestone payments. Read more>>>